Patents by Inventor Mehtap Saydam

Mehtap Saydam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical combinations of dabigatran and proton pump inhibitors
    Patent number: 10130618
    Abstract: This invention is a novel pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof in combination with a proton pump inhibitor for use in the antithrombotic treatment with preventing or reducing the risk of a gastrointestinal disorder.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 20, 2018
    Assignee: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
    Inventors: Ali Türkyilmaz, Mehtap Saydam, Yildiz Gülkok, Nur Kirat Uzunogullari, Sevgi Gökcek
  • Pharmaceutical formulations of vildagliptin
    Patent number: 9795592
    Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: October 24, 2017
    Assignee: Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Ali Turkyilmaz, Ali Hasan Turp, Mehtap Saydam, Onur Ulgen
  • PHARMACEUTICAL COMBINATIONS OF SITAGLIPTIN
    Publication number: 20170239276
    Abstract: A pharmaceutical combination comprising sitagliptin or a pharmaceutically acceptable salt thereof in combination with a sulfonylurea.
    Type: Application
    Filed: September 4, 2015
    Publication date: August 24, 2017
    Inventors: ONUR MUTLU, ALI TÜRKYILMAZ, GÜLAY YELKEN, MEHTAP SAYDAM
  • PHARMACEUTICAL COMBINATIONS OF DABIGATRAN AND PROTON PUMP INHIBITORS
    Publication number: 20170035745
    Abstract: This invention is a novel pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof in combination with a proton pump inhibitor for use in the antithrombotic treatment with preventing or reducing the risk of a gastrointestinal disorder.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 9, 2017
    Inventors: ALI TÜRKYILMAZ, MEHTAP SAYDAM, YILDIZ GÜLKOK, NUR KIRAT UZUNOGULLARI, SEVGI GÖKCEK
  • Pharmaceutical Formulations of Vildagliptin
    Publication number: 20170014379
    Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
    Type: Application
    Filed: March 5, 2015
    Publication date: January 19, 2017
    Inventors: Ali Turkyilmaz, Ali Hasan Turp, Mehtap Saydam, Onur Ulgen
  • Vildagliptin Formulation Process Under Inert Gas Atmosphere
    Publication number: 20170014380
    Abstract: The present invention relates to a process for preparing a pharmaceutical composition of vildagliptin under oxygen free inert gas atmosphere. The present invention particularly relates to a pharmaceutical composition of vildagliptin obtained by the process which is stable to oxygen physiologically and chemically.
    Type: Application
    Filed: March 5, 2015
    Publication date: January 19, 2017
    Inventors: Ali Turkyilmaz, Gulay Yelken, Mehtap Saydam, Onur Ulgen
  • DPP-IV INHIBITOR FORMULATIONS
    Publication number: 20140302150
    Abstract: The present invention relates to a pharmaceutical formulation, characterized by comprising a DPP-IV inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
    Type: Application
    Filed: September 5, 2012
    Publication date: October 9, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Gulay Yelken, Mehtap Saydam